This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 571

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax

By Adam Feuerstein

What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?

09:49AM 09/30/14

Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug

By Adam Feuerstein

For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.

07:20AM 09/30/14

Clovis Shares Higher on Improved Outlook for Lung Cancer Drug

By Adam Feuerstein

Clovis Oncology shares are higher Monday because AstraZeneca, its direct competitor to develop a new, genetically targeted lung cancer drug, slipped this weekend.

12:17PM 09/29/14

Seattle Genetics Seeks Expanded Use of Lymphoma Drug on Study Win

By Adam Feuerstein

Adcetris delayed disease progression in Hodgkin lymphoma patients following a stem cell transplant.

09:31AM 09/29/14

Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

07:00AM 09/26/14

Gilead Sciences' Next-Generation HIV Drug Hits the Mark

By Adam Feuerstein

TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.

10:30AM 09/24/14

Why Alcobra Investors Are So Nervous About a Coming Drug Study

By Adam Feuerstein

Results from a phase III study of Alcobra's MDX in adult ADHD are expected within the next week.

09:04AM 09/24/14

Merrimack Does Well to License Marginal Cancer Drug to Baxter

By Adam Feuerstein

Baxter has a hunger for cancer drugs with hair.

08:14AM 09/24/14

Tekmira Experimental Ebola Drug Used to Treat Stricken U.S. Doctor

By Adam Feuerstein

Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.

07:48PM 09/22/14

Gilead Sciences: A Preview of Important HIV Drug Study Results

By Adam Feuerstein

Gilead's goal is to create new versions of its blockbuster HIV combination therapies, replacing Viread with TAF.

12:44PM 09/22/14

« Back
Page 1 of 571

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs